- Home
- HURN vs AKRO Comparison
HURN vs AKRO Comparison
Compare HURN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- AKRO
- Stock Information
- Founded
- HURN 2002
- AKRO 2017
- Country
- HURN United States
- AKRO United States
- Employees
- HURN N/A
- AKRO N/A
- Industry
- HURN Professional Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- AKRO Health Care
- Exchange
- HURN Nasdaq
- AKRO Nasdaq
- Market Cap
- HURN N/A
- AKRO 2.1B
- IPO Year
- HURN 2004
- AKRO 2019
- Fundamental
- Price
- HURN $115.91
- AKRO $31.59
- Analyst Decision
- HURN Strong Buy
- AKRO Strong Buy
- Analyst Count
- HURN 4
- AKRO 7
- Target Price
- HURN $131.75
- AKRO $43.20
- AVG Volume (30 Days)
- HURN 66.1K
- AKRO 441.5K
- Earning Date
- HURN 10-29-2024
- AKRO 11-11-2024
- Dividend Yield
- HURN N/A
- AKRO N/A
- EPS Growth
- HURN 14.29
- AKRO N/A
- EPS
- HURN 4.16
- AKRO N/A
- Revenue
- HURN $1,425,021,000.00
- AKRO N/A
- Revenue This Year
- HURN $11.16
- AKRO N/A
- Revenue Next Year
- HURN $8.65
- AKRO N/A
- P/E Ratio
- HURN $25.27
- AKRO N/A
- Revenue Growth
- HURN 12.76
- AKRO N/A
- 52 Week Low
- HURN $84.26
- AKRO $11.36
- 52 Week High
- HURN $115.65
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- HURN 66.87
- AKRO 66.34
- Support Level
- HURN $103.24
- AKRO $29.34
- Resistance Level
- HURN $108.75
- AKRO $32.15
- Average True Range (ATR)
- HURN 2.06
- AKRO 1.26
- MACD
- HURN 0.22
- AKRO 0.10
- Stochastic Oscillator
- HURN 100.00
- AKRO 99.74
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.